Compare Crispr Therapeutics AG (CRSP) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PepsiCo, Inc. — how do they compare? Crispr Therapeutics AG trades at $51.2 (market cap $4.97B), while PepsiCo, Inc. trades at $135.21 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 37.2× Crispr Therapeutics AG's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PEP | |
|---|---|---|
Market Cap | $4.97B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $170.44 |
52-Week Low | $44.34 | $133.81 |
Enterprise Value | $3.32B | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
PepsiCo (PEP) trades at $135.92, down 1.86% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $93.93B in 2025, though net income margin dipped to 8.77%. Valuation ratios like a P/E of 17.75 and P/S of 1.92 appear reasonable. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while institutional investors show mixed activity.
The outlook is cautiously optimistic, supported by earnings beats and a 33% analyst buy rating, but near-term risks include competitive pressures and execution of pricing strategies. The consensus price target of $159.27 suggests upside potential, though technical weakness and margin pressures warrant monitoring. Key catalysts are Q3 2026 earnings and North American sales trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
